Literature DB >> 7520756

Ineffectiveness of the inhibition of the main haemorrhagic metalloproteinase from Bothrops jararaca venom by its only plasma inhibitor, alpha 2-macroglobulin.

A S Kamiguti1, H P Desmond, R D Theakston, C R Hay, M Zuzel.   

Abstract

Observations that a haemorrhagic metalloproteinase (jararhagin) from Bothrops jararaca venom had less effect on platelets suspended in plasma than in washed platelet suspensions, suggested that plasma contains naturally occurring inhibitor(s) of this enzyme. By using radiolabelled jararhagin and crossed immunoelectrophoresis, we have demonstrated the binding of this enzyme to alpha 2-macroglobulin in plasma. SDS-PAGE analysis of this binding revealed the presence of radioactivity in four bands with relative molecular masses of 640, 570, 520 and 410 kDa; in addition a small amount of 47 kDa free enzyme was demonstrable. Reduced samples showed an additional non-complexed 90 kDa fragment of alpha 2-macroglobulin generated by jararhagin. These results are compatible with a model in which, upon multiple cleavages of alpha 2-macroglobulin, the enzyme becomes covalently bound to the inhibitor, and the two halves of the inhibitor become crosslinked. However, jararhagin activity was not completely inhibited even after long incubation (60 min) with a large (10-fold) molar excess of alpha 2-macroglobulin either in plasma or a purified alpha 2-macroglobulin preparation. Kinetic studies showed that inhibition was comparatively slow, although jararhagin readily cleaved alpha 2-macroglobulin in the bait region. Therefore, the ineffectiveness of the inhibition could have resulted from a low tendency of this proteinase to form covalent complexes with the inhibitor. We conclude that the pronounced haemorrhagic activity of jararhagin can be attributed to prolonged access of this enzyme to high molecular weight substrates, even in the presence of a large molar excess of alpha 2-macroglobulin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520756     DOI: 10.1016/0304-4165(94)90172-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Antibody from mice immunized with DNA encoding the carboxyl-disintegrin and cysteine-rich domain (JD9) of the haemorrhagic metalloprotease, Jararhagin, inhibits the main lethal component of viper venom.

Authors:  R A Harrison; A M Moura-Da-Silva; G D Laing; Y Wu; A Richards; A Broadhead; A E Bianco; R D Theakston
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

2.  Inhibition of collagen-induced platelet aggregation as the result of cleavage of alpha 2 beta 1-integrin by the snake venom metalloproteinase jararhagin.

Authors:  A S Kamiguti; C R Hay; M Zuzel
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

3.  Role of collagens and perlecan in microvascular stability: exploring the mechanism of capillary vessel damage by snake venom metalloproteinases.

Authors:  Teresa Escalante; Natalia Ortiz; Alexandra Rucavado; Eladio F Sanchez; Michael Richardson; Jay W Fox; José María Gutiérrez
Journal:  PLoS One       Date:  2011-12-08       Impact factor: 3.240

4.  Extracts of Renealmia alpinia (Rottb.) MAAS Protect against Lethality and Systemic Hemorrhage Induced by Bothrops asper Venom: Insights from a Model with Extract Administration before Venom Injection.

Authors:  Arley Camilo Patiño; Juan Carlos Quintana; José María Gutiérrez; Alexandra Rucavado; Dora María Benjumea; Jaime Andrés Pereañez
Journal:  Toxins (Basel)       Date:  2015-04-30       Impact factor: 4.546

Review 5.  Hemorrhage Caused by Snake Venom Metalloproteinases: A Journey of Discovery and Understanding.

Authors:  José María Gutiérrez; Teresa Escalante; Alexandra Rucavado; Cristina Herrera
Journal:  Toxins (Basel)       Date:  2016-03-26       Impact factor: 4.546

6.  Cleavage of proteoglycans, plasma proteins and the platelet-derived growth factor receptor in the hemorrhagic process induced by snake venom metalloproteinases.

Authors:  Amanda F Asega; Milene C Menezes; Dilza Trevisan-Silva; Daniela Cajado-Carvalho; Luciana Bertholim; Ana K Oliveira; André Zelanis; Solange M T Serrano
Journal:  Sci Rep       Date:  2020-07-31       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.